Skip to Main Content

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Principal Investigator

Carl Landgren

Enrollment Status


Clinical Trial ID

Institutional Protocol # 20201536
National Clinical Trials Identifier NCT04814615

Clinical Trial Summary


Phase 2

Funding Agency/Sponsor

Externally Peer-Reviewed



Enrollment Eligibility

Inclusion Criteria:
1. Male or female ≥ 21 years of age
2. Histologically/immunohistochemistry-confirmed CD38-positive multiple myeloma
3. At least one tumor lesion on CT, MRI, or FDG PET/CT within 90 days of protocol
4. ECOG performance status 0 to 2
5. Written informed consent obtained from subject or subject's legal representative and
ability for subject to comply with the requirements of the study
Exclusion Criteria:
1. Pregnant, breastfeeding, or unwilling to practice birth control during participation
in the study.
2. Life expectancy < 12 months
3. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners
may not be able to function with patients over 450 pounds.
4. History of anaphylactic reaction to humanized or human antibodies.

Contact Information

Phone Number 305-243-2647
Get detailed information on ClinicalTrials.Gov